WO2001015776A1 - Irradiation device - Google Patents

Irradiation device Download PDF

Info

Publication number
WO2001015776A1
WO2001015776A1 PCT/SE2000/001635 SE0001635W WO0115776A1 WO 2001015776 A1 WO2001015776 A1 WO 2001015776A1 SE 0001635 W SE0001635 W SE 0001635W WO 0115776 A1 WO0115776 A1 WO 0115776A1
Authority
WO
WIPO (PCT)
Prior art keywords
radiation
substance
phototoxic
skin
photoproducts
Prior art date
Application number
PCT/SE2000/001635
Other languages
English (en)
French (fr)
Inventor
Fredrik Gudmundson
Original Assignee
Medeikonos Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeikonos Ab filed Critical Medeikonos Ab
Priority to EP00957216A priority Critical patent/EP1207940A1/en
Priority to AU68868/00A priority patent/AU6886800A/en
Priority to CA002381824A priority patent/CA2381824A1/en
Publication of WO2001015776A1 publication Critical patent/WO2001015776A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0635Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0642Irradiating part of the body at a certain distance

Definitions

  • the present invention relates to a device for treating skin changes, especially skin tumours, said device comprising a radiation unit for radiation of a phototoxic substance accumulated in the skin changes, a cytotoxic effect arising in radiation of the phototoxic substance.
  • the invention also relates to a method for radiation of a phototoxic substance, and a method of determining a suitable wavelength range for treating skin changes.
  • ALA delta- aminolevulinic acid
  • the ALA substance is allowed to act on the skin for e.g. 1-24 h, and in the meantime protoporphyrin IX is formed in the skin area.
  • Protoporphyrin IX is formed or accumulated in a larger amount in the parts of the area which contain a skin change, compared with other skin portions.
  • Protoporphyrin IX is a substance with several useful properties. First, the substance fluoresces, which can be used to detect skin changes (see Swedish patent application No. 9603095-2) . Second, protoporphyrin IX has a phototoxic effect in long-term radiation of the substance. This can be used to cause cell death in the skin area containing protoporphyrin IX and, thus, remove the skin change .
  • the phototoxic effect is currently used for treating skin tumours.
  • the skin area in question is then usually radiated with a broad spectrum lamp which covers the entire red band of the visible spectrum, with wavelengths of 570-680 nm, a phototoxic reaction occurring in the protoporphyrin IX which has accumulated in the tumour, thus killing the cancer cells.
  • a disadvantage of this technique is that the treatment causes pain in the patient. Especially in radiation of extensive skin areas, such as about 100 cm 2 , and skin areas with sensi- tive skin, this pain is difficult to endure, and therefore the treatment must in many cases be interrupted. Examples of diseases where this pain is a heavy problem is facial actinic keratosis and vulval dysplasia.
  • Another prior art technique of using the phototoxic effect for treatment is to use a laser instead of a broad spectrum lamp.
  • the wavelength of the light emitted by the laser is selected in the vicinity of a light absorption peak of protoporphyrin IX, usually about 630 nm.
  • the laser For treatment of a large skin area, the laser must be successively moved back and forth over the surface, which causes a risk that part of the area will not be radiated and, thus, a risk of insufficient treatment.
  • such a treatment takes a long time and requires great accuracy.
  • a further disadvantage is the relatively high cost of a laser.
  • the object of the present invention is to provide a device which does not have the above disadvantages, i.e. with which extensive skin areas can be quickly and easily treated while the patient's experience of pain is kept relatively low.
  • a device as described by way of introduction in which the selected phototoxic substance forms new substances, so-called photoproducts, in radiation from the radiation unit, and the radiation unit is adapted to generate broad spectrum radiation in a selected wavelength range, in which a relatively high photoabsorption in the phototoxic substance and a rela- tively low photoabsorption in the photoproducts are obtained.
  • the radiation spectrum that is generated by the inventive device is still to be considered a broadband spectrum and can therefore easily be used to treat a large skin area, in contrast to the previously mentioned laser method.
  • the radiation unit in the device according to the invention can suitably be obtained with the aid of a broad spectrum radiation source, which is fitted with a suitable filtering device to obtain the desired wavelength range.
  • the phototoxic substance can advantageously be a substance of the type which has the property that it is formed or accumulated selectively in skin changes.
  • the device can be adapted to a phototoxic substance of the type which is formed in skin when applying a substance which contains a compound or composition containing deltaaminolevulinic acid (ALA) .
  • the phototoxic substance can preferably be protoporphyrin IX.
  • the wavelength spectrum from the radiation unit suitably lacks essentially radiation with wavelengths outside the range 600-655 nm and in particular 610-645 nm.
  • a wavelength spectrum is particularly preferred, which essentially lacks radiation with wavelengths outside the range 610-635 nm.
  • the peaks in the absorption spectrum of protoporphyrin IX which are positioned in the short-wave part of the spectrum generally have too low penetration capacity in skin, and therefore cannot be used for the purpose of completely removing skin changes.
  • the invention also relates to a method as mentioned by way of introduction, in which the phototoxic substance is radiated with a wavelength range in which a relatively high photoabsorption in the phototoxic substance and a relatively low photoabsorption in the photoproducts are
  • the invention relates to a method of determining a suitable wavelength range for treating a skin change.
  • the method comprises an examination of the photoabsorption for a selected phototoxic substance and its photoproducts.
  • the range is selected, in which a relatively high photoabsorption in the phototoxic substance and a relatively low photoabsorption in the photoproducts are obtained.
  • the range can advantageously be refined by excluding wavelengths whose penetration capac- ity in skin is insufficient for complete treatment of the skin tumour.
  • the examination of the absorption capacities can advantageously occur in solution or suspension of the substances, which allows a simple examination method in laboratory environment .
  • a device is thus provided, which makes it possible to treat a relatively extensive skin area, quickly and easily and without intolerable pain being experienced by the patient.
  • a method is provided for radiation of a photoreactive substance, and according to a third aspect, a method of determining a suitable wavelength range for treating skin changes by means of phototoxic substances.
  • FIG. 1 is a principle sketch of an embodiment of a device according to the invention.
  • Fig. 2 shows the absorption spectrum of protoporphyrin IX and its photoproducts.
  • Fig. 3 shows the integrated absorption of protopor- phyrin IX and its photoproducts between 600 and 700 nm, and the ratio of these two absorption curves.
  • Fig. 1 is a principle sketch of the device according to the invention.
  • a radiation unit 1 is shown, which radiates a skin area 2.
  • a broad spectrum lamp 3 emitting light preferably in the red band of the visible spectrum, is arranged in a casing 4 which is formed with an opening 5 for emitted light.
  • the casing 4 is articulated to an arm 6, which in turn is articulated, for easy shifting and setting of the unit 1 relative to the skin area 2 of the patient.
  • Behind the lamp 3, reflectors 7 are arranged in the casing 4 to catch and direct all light towards the opening 5.
  • a filter unit 8 is arranged, which filters the light emitted by the lamp 3.
  • Fig. 2 shows the photoabsorption of protoporphyrin IX (full line) and its photoproducts (dashed line) . It can here be seen that the photoabsorption of the photo- products is low at wavelengths in the range 600-655 nm. In this range, there is also a photoabsorption peak of protoporphyrin IX in the range 610-645 nm. This justifies the choice of a broad spectrum lamp which together with a filter produces a radiation spectrum which essentially lacks radiation outside the wavelength range 600-655 nm and especially outside the wavelength range 610-645 nm. Fig.
  • the device was allowed to radiate a large skin area, and the treatment time was the same as for a broadband lamp according to prior art technique.
  • a conceivable explanation of the pain when using prior art technique is that protoporphyrin IX decomposes into other substances, so-called photoproducts, under the action of light.
  • the new substances have, in turn, absorption peaks which are positioned at other wave- lengths than that of protoporphyrin IX, but within the wavelength ranges that are used in prior art devices. As the treatment proceeds, more and more energy is thus absorbed, and the pain becomes more and more intense.
  • phototoxic substances can be used, which require radiation spectra that are es- pecially adapted thereto.
  • the radiation unit can be designed in a manner other than that described, with a broadband lamp and an adapted filter.
  • a lamp can be constructed which, unfiltered, emits the desired spectrum.
  • the method can be used, inter alia, for studies of phototoxic substances in laboratories or on tissue samples in vitro.
  • the method of determining a suitable wavelength range for treatment of skin changes by means of a phototoxic substance can also be used for other photoreactive substances than those stated in the description.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiation-Therapy Devices (AREA)
PCT/SE2000/001635 1999-08-27 2000-08-24 Irradiation device WO2001015776A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00957216A EP1207940A1 (en) 1999-08-27 2000-08-24 Irradiation device
AU68868/00A AU6886800A (en) 1999-08-27 2000-08-24 Irradiation device
CA002381824A CA2381824A1 (en) 1999-08-27 2000-08-24 Irradiation device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903057-9 1999-08-27
SE9903057A SE9903057L (sv) 1999-08-27 1999-08-27 Belysningsanordning

Publications (1)

Publication Number Publication Date
WO2001015776A1 true WO2001015776A1 (en) 2001-03-08

Family

ID=20416793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/001635 WO2001015776A1 (en) 1999-08-27 2000-08-24 Irradiation device

Country Status (5)

Country Link
EP (1) EP1207940A1 (sv)
AU (1) AU6886800A (sv)
CA (1) CA2381824A1 (sv)
SE (1) SE9903057L (sv)
WO (1) WO2001015776A1 (sv)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007077A1 (en) * 1993-09-10 1995-03-16 The Norwegian Radium Hospital Research Foundation Photochemotherapeutic compositions containing 5-aminolevulinic acid
WO1996039188A1 (en) * 1995-06-05 1996-12-12 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007077A1 (en) * 1993-09-10 1995-03-16 The Norwegian Radium Hospital Research Foundation Photochemotherapeutic compositions containing 5-aminolevulinic acid
WO1996039188A1 (en) * 1995-06-05 1996-12-12 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins

Also Published As

Publication number Publication date
SE9903057D0 (sv) 1999-08-27
EP1207940A1 (en) 2002-05-29
CA2381824A1 (en) 2001-03-08
AU6886800A (en) 2001-03-26
SE9903057L (sv) 2001-02-28

Similar Documents

Publication Publication Date Title
Van Gemert et al. Wavelength and light-dose dependence in tumour phototheraphy with haematoporphyrin derivative
Finlay et al. Photobleaching kinetics of Photofrin in vivo and in multicell tumour spheroids indicate two simultaneous bleaching mechanisms
US5707401A (en) Apparatus for an efficient photodynamic treatment
EP1100366B1 (en) Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea
CA2343843A1 (en) Therapeutic light source and method
JP2002522110A (ja) 光エネルギを用いた色素沈着組織の治療方法
HU186081B (en) Process and apparatus for stimulating healing of pathologic points on the surface of the body first of all of wounds, ulcera and other epithelial lesions
BENSON Jr Laser photodynamic therapy for bladder cancer
Whitehurst et al. Development of an alternative light source to lasers for photodynamic therapy: 1. Comparative in vitro dose response characteristics
CA2112444A1 (en) Medical Laser Apparatus and Diagnosing/Curing Apparatus Using the Medical Laser Apparatus
Moseley Total effective fluence: a useful concept in photodynamic therapy
US20070032844A1 (en) Targeted UV phototherapy light block
CA2947392C (en) Apparatus and method for multiwavelength photodynamic therapy
Gottfried et al. Vascular damage during PDT as monitored in the chick chorioallantoic membrane
EP1207940A1 (en) Irradiation device
Ueda et al. Unfiltered xenon light is useful for photodynamic therapy with acridine orange
Whitehurst et al. Performance of a nonlaser light source for photodynamic therapy
Kochevar Photobiology. Basic science.
WO1997020596A1 (en) Therapy apparatus and method
Ion et al. Laser effect in photodynamic therapy of tumors
Whitehurst et al. Development of an alternative light source to lasers for photodynamic therapy: 2. Comparative in vivo tumour response characteristics
Meerovich et al. Phosphosubstituted phthalocyanine derivatives as effective photosensitizers for PDT
AU696682B2 (en) Apparatus for an efficient photodynamic treatment
Vesper et al. Photodynamic therapy (PDT): an evolving therapeutic technique in head and neck cancer treatment
Vaucher et al. Sparing of normal urothelium in hexyl-aminolevulinate-mediated photodynamic therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000957216

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2381824

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 68868/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10069022

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000957216

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000957216

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP